Direct-acting oral anticoagulants have emerged as the preferred anticoagulant class for many patients due to the safety profile, efficacy, and ease of use. However, patients with obesity were excluded from the initial clinical trials raising concerns about external validity for this population. Join us to learn the role of rivaroxaban for stroke and venous thromboembolism prevention in patients with obesity.

Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
1. Describe the efficacy of rivaroxaban for stroke prevention in atrial fibrillation in patients with obesity
2. Describe the efficacy of rivaroxaban for venous thromboembolism prevention in patients with obesity
3. Compare the risk of bleeding and hospital length of stay with rivaroxaban versus warfarin in patients with obesity
4. Analyze limitations for use of rivaroxaban in patients with obesity
5. Develop a conclusion for the clinical appropriateness of care based on a clinical trial.

Billie Bartel, PharmD, BCCCP
Clinical Pharmacist
Sanford Aberdeen Medical Center

Billie Bartel does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course. 

CEimpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:

Perales I, San Agustin K, DeAngelo J, et al. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight. Annals of Pharmacotherapy 2020; 54(4) 344-350. DOI: 10.1177/1060028019886092.

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

This course is included in our Pharmacist Subscription Services. To get more courses like this sent to you every month, sign-up for a CE Subscription Service!

Fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: March 10, 2021
Planned Expiration Date: March 10, 2024